Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours

Next Previous
Trial Profile

A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VAL 201 (Primary)
  • Indications Carcinoma; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms VAL201-001
  • Sponsors ValiRx

    • Most Recent Events

    • 20 May 2020 Status changed from completed to discontinued.
    • 14 Feb 2020 Status changed from recruiting to completed.
    • 06 Jan 2020 According to an ValiRx media release, the company has raised 200,000 pounds of gross proceeds through the issue of 200,000,000 new ordinary shares. These net proceeds of the Placing will be used to analyse this Phase I/II clinical trial of VAL201.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top